ALX Oncology Inc. (ALXO)
ALX Oncology Statistics
Share Statistics
ALX Oncology has 53.38M shares outstanding. The number of shares has increased by 2.46% in one year.
| Shares Outstanding | 53.38M |
| Shares Change (YoY) | 2.46% |
| Shares Change (QoQ) | 1.22% |
| Owned by Institutions (%) | 77.93% |
| Shares Floating | 33.99M |
| Failed to Deliver (FTD) Shares | 39 |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 6.3M, so 11.94% of the outstanding shares have been sold short.
| Short Interest | 6.3M |
| Short % of Shares Out | 11.94% |
| Short % of Float | 20.68% |
| Short Ratio (days to cover) | 13.28 |
Valuation Ratios
The PE ratio is -0.65 and the forward PE ratio is -0.41. ALX Oncology's PEG ratio is 0.02.
| PE Ratio | -0.65 |
| Forward PE | -0.41 |
| PS Ratio | 0 |
| Forward PS | 0.3 |
| PB Ratio | 0.77 |
| P/FCF Ratio | -0.71 |
| PEG Ratio | 0.02 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for ALX Oncology.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.26, with a Debt / Equity ratio of 0.
| Current Ratio | 7.26 |
| Quick Ratio | 7.26 |
| Debt / Equity | 0 |
| Debt / EBITDA | 0 |
| Debt / FCF | 0 |
| Interest Coverage | -82.4 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-1.69M |
| Employee Count | 80 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -96.44% in the last 52 weeks. The beta is 1.2, so ALX Oncology's price volatility has been higher than the market average.
| Beta | 1.2 |
| 52-Week Price Change | -96.44% |
| 50-Day Moving Average | 0.81 |
| 200-Day Moving Average | 1.95 |
| Relative Strength Index (RSI) | 44.63 |
| Average Volume (20 Days) | 864.71K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -142.47M |
| Net Income | -134.85M |
| EBITDA | -132.25M |
| EBIT | -133.12M |
| Earnings Per Share (EPS) | -2.58 |
Balance Sheet
The company has 17.57M in cash and 435K in debt, giving a net cash position of 17.13M.
| Cash & Cash Equivalents | 17.57M |
| Total Debt | 435K |
| Net Cash | 17.13M |
| Retained Earnings | -621.12M |
| Total Assets | 147.78M |
| Working Capital | 115.85M |
Cash Flow
In the last 12 months, operating cash flow was -121.91M and capital expenditures -447K, giving a free cash flow of -122.36M.
| Operating Cash Flow | -121.91M |
| Capital Expenditures | -447K |
| Free Cash Flow | -122.36M |
| FCF Per Share | -2.35 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ALXO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for ALXO is $3, which is 400% higher than the current price. The consensus rating is "Buy".
| Price Target | $3 |
| Price Target Difference | 400% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Scores
| Altman Z-Score | -7.36 |
| Piotroski F-Score | 3 |